MG2 Checkweigher Operates at High Speeds - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MG2 Checkweigher Operates at High Speeds


The MG2 Selekta is a high-speed checkweigher and sorting machine for tablet production. Selekta offers flexibility in the product shapes and sizes it can handle.  Depending on the product, Selekta can check up to 500,000 units per hour and is designed for integration with continuous-processing tableting equipment. Selekta incorporates MG2's Multi-NETT weight-control system that can monitor and control net weight in low-dose applications (5–25mg). The machine selects conforming and nonconforming units through a fail-safe system employing a set of sensors located at critical points throughout the testing process. The unit can be directly connected downstream from primary production equipment, upstream of blister lines, or used as a standalone unit with automatic or manual load. Two special versions of Selekta are available for integration into packaging lines where tablets are placed into bottles: Selekta/CW performs product counting as well as weighing, and Selekta/C's sole function is counting.

Source: MG2

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here